Sign in
Taking peoplePhase 3

Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)

Key facts

Who runs it
Unity Health Toronto
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
264 people, planned
Started
29 Apr 2026
Expected to end
24 Apr 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Baloxavir
  • Placebo Control
Record updated
18 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • 18 years or older
  • A positive test (PCR or RAT) for one of the pathogens included in the trial's domains (influenza A/B, or other future specified respiratory pathogens),
  • Enrolled within 5 days of symptoms onset. However, this window may vary depending on the domain or specific interventions within each domain (for example 72 hours for Baloxavir)
  • At least two symptoms commonly associated with respiratory infections, including:; rhinitis; cough; wheezing; sore throat; nasal congestion; shortness of breath; fatigue; rapid breathing; excessive mucus production; loss of smell or taste; hemoptysis; trouble sleeping or insomnia due to breathing difficulties; fever (defined for purposes of this study as >37.5°C/ 41)

Who cannot take part

  • Previously randomized to TreatResp within the past 12 months
  • Is scheduled for elective surgery or procedures requiring general anesthesia within the next two weeks
  • Received a live viral vaccine within the last 14 days
  • Currently participating in a clinical trial of a therapeutic agent for acute respiratory pathogen infection that is not/suspected not compatible with the study therapeutics
  • Has severe hepatic impairment, or requires a live viral vaccine within the next seven days
  • Has a significant impaired immunity (e.g., due to long-term oral steroids, chemotherapy, or an immune disorder)
  • Is allergic to trial medications
  • Is co-infected with viruses of interest
  • Has advanced chronic kidney disease (CKD stage 3: eGFR ≥30 to <60 mL/min, and severe renal impairment (eGFR <30 ml/min, CKD stage 4-5)
  • Admitted to hospital or in an ED for more than 24 hours
  • Already taking a study therapeutic or contraindication to a study therapeutic
  • Inability for participant or caregiver to provide informed consent; Additional eligibility criteria will be applied based on the intervention assigned. For instance, if a participant is randomized to an antiviral treatment, they must not have contraindications specific to that antiviral. This ensures that each treatment is evaluated in a population for whom it is most appropriate and safe; Baloxavir exclusion:
  • Has a known or suspected pregnancy
  • Is breastfeeding
  • Is of childbearing potential and is not willing to use a highly effective contraceptive
  • Requires immediate antiviral treatment or hospitalization as per the clinician's judgment

This trial is currently available in Canada.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.

The 2 groups in the trial

  • Acute Influenza A/B - Matched placebo for BaloxavirPlacebo, for comparison

    Usual Care (i.e., supportive care and symptom relief). Matching control placebo for Baloxavir - a single matching dose.

    Treatment: Placebo Control

  • Acute Influenza A/B - BaloxavirTreatment being tested

    The adaptative platform trial will assess therapeutics for influenza A/B in out-patient setting. Interventions include: Baloxavir. Baloxavir dose: if weight \<80 kg: one 40 mg dose for 1 day; if weight ≥80kg, one 80 mg dose for one day.

    Treatment: Baloxavir

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings
Record updated
18 August 2026